Liberant is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous ...

FAIRFAX, Va., Oct. 31, 2025 /PRNewswire/ -- A new review of Medicare data shows a marked increase for both arterial and venous thrombectomy claims for venous thromboembolic disease filed between ...

In a study of patients with RCC and venous thrombus who underwent radical nephrectomy and venous thrombectomy, the median overall survival was 56 months. Patients with renal cell carcinoma (RCC) can ...

Relieving venous congestion using thrombectomy may preserve kidney function in RCC with IVC tumor thrombus.

Medtronic announced the first commercial use of the Liberant thrombectomy system, which is indicated for the removal of fresh, ...

Recana Thrombectomy Catheter System is designed to address the challenges of venous in-stent restenosis and residual thrombotic obstructions and occlusions. REDWOOD CITY, Calif., October 31, ...

Blood clots represent a significant burden to the healthcare system. Venous thromboembolism (VTE) includes blood clots that form in the deep veins of the legs, as well as those in the lungs. A clot ...

Dissatisfaction with the high incidence of postphlebitic limb after massive deep thrombophlebitis has prompted the use of thrombectomy in an attempt to diminish this discouraging complication. In the ...

Deal adds second FDA 510(k) cleared device to thrombectomy platform Easy-to-use, stand-alone, single session mechanical thrombectomy for removal of venous clot in highly attractive, rapidly growing ...

InterVene Receives FDA 510(k) Clearance for Recana®, the First Fully Integrated Thrombectomy System for Venous In-Stent Restenosis and Native Vessel Obstructions Recana Thrombectomy Catheter System is ...